Because of evidence that supports an important role for the 5-HT1A receptor subtype in migraine, buspirone--the novel 5-HT1A receptor agonist with anxiolytic properties--was given to 33 patients suffering from severe migraine exacerbations. Patients took 15-20 mg/daily for 10 weeks; six (18%) patients did not improve. Although buspirone was well tolerated, two additional patients (6%) did not finish the trial, due to undesirable side effects. On the other hand, 25 (76%) patients improved; 17 (52%) exhibited an excellent response; and 8 (24%), a moderate response. Potential reasons for the observed antimigraine effect of buspirone and its possible consequences in migraine pathophysiology are discussed. Our results, at first, seem to support the role of a 5-HT1A hypersensitivity in migraine pathogenesis, and warrant further trials to confirm whether buspirone represents an alternative in preventive treatment of migraine exacerbations.
No takes yet. Share an insight, caveat, or question.
Pascual et al. (1991) studied this question.